title: 5-HT4 receptor agonists: similar but not the same.
abstract: 5-Hydroxytryptamine(4) (5-HT(4)) receptors are an interesting target for the management of patients in need of gastrointestinal (GI) promotility treatment. They have proven therapeutic potential to treat patients with GI motility disorders. Lack of selectivity for the 5-HT(4) receptor has limited the clinical success of the agonists used until now. For instance, next to their affinity for 5-HT(4) receptors, both cisapride and tegaserod have appreciable affinity for other receptors, channels or transporters [e.g. cisapride: human ether-a-go-go-related gene (hERG) is K(+) channel and tegaserod: 5-HT(1) and 5-HT(2) receptors]. Adverse cardiovascular events observed with these compounds are not 5-HT(4) receptor-related. Recent efforts have led to the discovery of a series of selective 5-HT(4) receptor ligands, with prucalopride being the most advanced in clinical development. The selectivity of these new compounds clearly differentiates them from the older generation compounds by minimizing the potential of target-unrelated side effects. The availability of selective agonists enables the focus to shift to the exploration of 5-HT(4) receptor-related differences between agonists. Based on drug- and tissue-related properties (e.g. differences in receptor binding, receptor density, effectors, coupling efficiency), 5-HT(4) receptor agonists are able to express tissue selectivity, i.e. behave as a partial agonist in some and as a full agonist in other tissues. Furthermore, the concept of ligand-directed signalling offers great opportunities for future drug development by enlarging the scientific basis for the generation of agonist-specific effects in different cell types, tissues or organs. Selective 5-HT(4) receptor agonists might thus prove to be innovative drugs with an attractive safety profile for better treatment of patients suffering from hypomotility disorders.
authors.affiliation: Movetis NV, Turnhout, Belgium. jdemaeyer@movetis.com
authors.forename: J H
authors.initials: JH
authors.lastname: De Maeyer
authors.forename: R A
authors.initials: RA
authors.lastname: Lefebvre
authors.forename: J A J
authors.initials: JA
authors.lastname: Schuurkes
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D005767:Gastrointestinal Diseases / Q000188:drug therapy / Q000503:physiopathology; D005769:Gastrointestinal Motility / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D058828:Serotonin 5-HT4 Receptor Agonists; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*
chemical_list: D005765:Gastrointestinal Agents; D058828:Serotonin 5-HT4 Receptor Agonists; D017366:Serotonin Receptor Agonists